Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A preparation method of anticoagulant modified membrane for extracorporeal circulation

An extracorporeal circulation and anticoagulation technology, applied in the field of medicine, can solve the problems of inability to directly inhibit the core-Xa factor, aggravate the bleeding risk of critically ill patients, and the large molecular weight of heparin-like substances, so as to avoid steric hindrance effects and achieve strong anti-inflammatory effects. Coagulant and antithrombotic properties, reducing thrombocytopenia

Active Publication Date: 2022-04-15
XIANGYA HOSPITAL CENT SOUTH UNIV +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the embodiments of the present invention is to provide a method for preparing an anticoagulant modified membrane for extracorporeal circulation, to solve the problem that the anticoagulant modified membrane in the prior art cannot directly inhibit the core of the coagulation pathway-factor Xa, and the existing anticoagulant modified membrane Aggravate the risk of bleeding in critically ill patients, and the drug heparin grafted with extracorporeal circulation membrane material has a large molecular weight and a large spatial conformation, which is not conducive to membrane modification

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A preparation method of anticoagulant modified membrane for extracorporeal circulation
  • A preparation method of anticoagulant modified membrane for extracorporeal circulation
  • A preparation method of anticoagulant modified membrane for extracorporeal circulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Step 1, synthesis of carboxylated polysulfone / polyethersulfone

[0033] Dissolve 10g of polysulfone / polyethersulfone in 40ml of NMP and stir to form a homogeneous solution, slowly blow in nitrogen, and then add 4.5g of anhydrous AlCl in sequence 3 , 6ml C 2 h 3 ClO and 100ml NMP, adjust the temperature of the reaction system to 70°C, and react for 2h. The reacted solution was washed 3 times with absolute ethanol and dried to obtain acetylated polysulfone / polyethersulfone (PSf / PES-COCH 3 ).

[0034] 10g of acetylated polysulfone / polyethersulfone (PSf / PES-COCH 3 ) was dissolved in 40ml NMP and stirred to form a homogeneous solution, and then 1g KMnO 4 , 3.7g NaOH, 9g double distilled water, 40ml NMP, adjust the temperature of the reaction system to 70°C, and react for 4h. The reacted solution was washed three times with dilute hydrochloric acid at pH=1 to obtain carboxylated polysulfone / polyethersulfone (PSf / PES-COOH).

[0035] Step 2, synthesis of apixaban modified ...

Embodiment 2

[0041] Step 1, synthesis of carboxylated polysulfone / polyethersulfone:

[0042] Dissolve 10g of polysulfone / polyethersulfone in 40ml of NMP and stir to form a homogeneous solution, slowly blow in nitrogen, and then add 5.5g of anhydrous AlCl in sequence 3 , 8ml C 2 h 3 ClO and 100ml NMP, adjust the temperature of the reaction system to 90°C, and react for 2h. The reacted solution was washed 3 times with absolute ethanol and dried to obtain acetylated polysulfone / polyethersulfone (PSf / PES-COCH 3 ).

[0043] Dissolve 10g acetylated polysulfone / polyethersulfone in 40ml NMP and stir to form a homogeneous solution, then add 1.2g KMnO4, 3.8g NaOH, 9g double distilled water, 40ml NMP in sequence, adjust the temperature of the reaction system to 80°C, and react for 6h . The reacted solution was washed three times with dilute hydrochloric acid at pH=1 to obtain carboxylated polysulfone / polyethersulfone (PSf / PES-COOH).

[0044] Step 2, synthesis of apixaban modified polysulfone / po...

Embodiment 3

[0049] Step 1, synthesis of carboxylated polysulfone / polyethersulfone:

[0050] Dissolve 10g of polysulfone / polyethersulfone in 40ml of NMP and stir to form a homogeneous solution, slowly blow in nitrogen, and then add 5g of anhydrous AlCl in sequence 3 , 7ml C 2 h 3 ClO and 100ml NMP, adjust the temperature of the reaction system to 80°C, and react for 2h. The reacted solution was washed 3 times with absolute ethanol and dried to obtain acetylated polysulfone / polyethersulfone (PSf / PES-COCH 3 ).

[0051] Dissolve 10g acetylated polysulfone / polyethersulfone in 40ml NMP and stir to form a homogeneous solution, then add 1.1g KMnO4, 3.75g NaOH, 9g double distilled water, 40ml NMP in sequence, adjust the temperature of the reaction system to 75°C, and react for 5h . The reacted solution was washed three times with dilute hydrochloric acid at pH=1 to obtain carboxylated polysulfone / polyethersulfone (PSf / PES-COOH).

[0052] Step 2, synthesis of apixaban modified polysulfone / pol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of an anticoagulant modified membrane for extracorporeal circulation, which comprises the following steps: step 1, synthesizing carboxylated polysulfone / polyethersulfone, step 2, synthesizing apixaban modified polysulfone / polyether Sulfone, step 3, preparing apixaban-modified polysulfone / polyethersulfone membrane. The present invention provides an extracorporeal circulation anticoagulant modified membrane and a preparation method thereof, in which apixaban, a factor Xa inhibitor, is grafted onto substrates such as polyethersulfone (PES), polysulfone (PSf), etc., and apixaban is used to The Shaban modified base material can efficiently inhibit the thrombus attached to the wall of the membrane material through signal amplification, so that it has strong anticoagulant and antithrombotic properties. The modification process has simple synthesis conditions, strong controllability, and is suitable for subsequent industrialized large-scale production. The novel extracorporeal circulation anticoagulant modified membrane effectively avoids the steric hindrance effect caused by heparin / heparanoid synthesis, and at the same time reduces the risk of aggravated bleeding caused by heparin-induced thrombocytopenia (HIT).

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a preparation method of an anticoagulant modified membrane for extracorporeal circulation. Background technique [0002] Extracorporeal circulation therapy based on artificial kidney, artificial liver and extracorporeal membrane oxygenation (ECMO) has become an important means of treatment for critical illness. The extracorporeal circulation membrane material is in direct contact with human blood, which is easy to induce coagulation and thrombus, so anticoagulant / antithrombotic treatment must be routinely performed clinically during the above treatments. The contact between membrane material and blood is the initiating factor of blood coagulation in extracorporeal circulation therapy, and the membrane / blood interface is the key part of coagulation and thrombus. The performance of the membrane material determines its biological reaction with human blood, and determin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): B01D67/00B01D69/02
CPCB01D67/0006B01D67/0093B01D67/0002B01D69/02
Inventor 府晓彭捷洪丹宁建平刘雁峰邹浪汤赐
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com